Nasobec (Beclometasone Dipropionate)

Beclometasone dipropionate binds to glucocorticoid receptors in nasal epithelial cells, altering gene expression. This suppresses the production of inflammatory cytokines and mediators, leading to decreased swelling, mucus production, and overall nasal inflammation.

The appropriate dose of Nasobec is determined by a qualified prescriber based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the dosing instructions provided on the prescription label and by their healthcare professional.

Safety data for beclometasone dipropionate in pregnancy and lactation are limited. Healthcare providers typically weigh potential benefits against risks before prescribing. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To request Nasobec, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasobec (beclometasone dipropionate) offers a potent anti‑inflammatory effect with a relatively low systemic absorption profile, similar to other intranasal steroids like fluticasone or mometasone. Choice among them often depends on physician preference, patient response, and formulation availability.

Nasobec should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight to maintain product stability.

Nasobec is administered as a nasal spray. The patient gently tilts the head forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include fungal infection of the nasal mucosa, severe nosebleeds, adrenal suppression with prolonged high‑dose use, and allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Nasobec should be avoided in individuals with known hypersensitivity to beclometasone dipropionate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections or recent nasal surgery unless advised by a physician.